medwireNews: Ticagrelor as a monotherapy rather than in conjunction with aspirin is associated with a reduced risk for clinically relevant bleeding in patients with acute coronary syndrome who have had percutaneous coronary intervention (PCI), show findings from the ULTIMATE-DAPT trial.
26-04-2024 | Acute Coronary Syndrome | News